蛋白质组学在神经退行性疾病中的研究进展

蛋白质组学是后基因组时代兴起的新型学科,是从整体水平对蛋白质的综合分析。阿尔茨海默病、帕金森病、肌萎缩侧索硬化症等是最常见的神经退行性疾病。应用蛋白质组学对它们进行研究,不仅可从蛋白质水平上揭示疾病的本质,还有助于全面探讨其病理机制,建立诊断标准,发现药物治疗靶点。     

蛋白质组学对于阿尔茨海默症诊断标记物筛选的研究进展

阿尔茨海默症,简称AD(Alzheimer's Disease),是一类神经退行性疾病,主要发作于65岁以上老年人群中,患者会出现认知障碍、记忆缺失、言语障碍、抑郁、焦躁等症状,逐渐失去生活自理能力,目前已经成为严重的社会卫生问题。疾病中晚期实施的药物干预与治疗难以逆转病情,效果甚微,由于病理机制不明以及缺乏早期诊断标准,难以在疾病早期进行干预和治疗。好的生物标记物(biomarker)可在分子水平上为疾病提供敏感而稳定的诊断手段,蛋白质组学可高通量地识别样本中的蛋白质并对其含量进行分析,所以近些年来很多研究者们使用蛋白质组学手段进行了疾病诊断标记物的筛选。本文就利用蛋白质组学手段进行阿尔茨海默症诊断标记物筛选的研究进展做一论述。     

阿尔茨海默氏病相关蛋白质及其作用机制研究进展

蛋白质组学技术被广泛的用于阿尔茨海默氏病(AD)的研究中.本文综述了已发现的AD脑组织、外周组织和动物模型中蛋白质差异表达和翻译后修饰变化,结合生物信息学分析结果,初步阐明了参与AD发病机制的关键蛋白质及其信号通路,为深入研究AD的病理生理机制和治疗提供了依据.     

蛋白质组学及其在肿瘤研究中的应用

简要介绍了蛋白质组学的概念、研究方法及其在肿瘤研究中的应用.蛋白质组学研究直接定位于蛋白质水平,从整体、动态、定量的角度去研究基因的功能,是后基因组计划的一个重要组成部分.恶性肿瘤是一种多基因参与的复杂疾病,从蛋白质整体水平上研究恶性肿瘤将有助于进一步揭示恶性肿瘤的发病机制,发现恶肿瘤特异性的标志物及其药物治疗的靶标.     

蛋白质组学及其在肿瘤研究中的应用

简要介绍了蛋白质组学的概念、研究方法及其在肿瘤研究中的应用.蛋白质组学研究直接定位于蛋白质水平，从整体、动态、定量的角度去研究基因的功能，是后基因组计划的一个重要组成部分.恶性肿瘤是一种多基因参与的复杂疾病，从蛋白质整体水平上研究恶性肿瘤将有助于进一步揭示恶性肿瘤的发病机制，发现恶性肿瘤特异性的标志物及其药物治疗的靶标.     

药物成瘾的蛋白质组学研究

药物成瘾涉及脑内多种蛋白含量、结构及功能的复杂改变,主要涉及代谢酶类、细胞骨架蛋白、分子伴侣、细胞内信号途径相关蛋白、突触功能相关蛋白和氧化还原相关蛋白等类型。蛋白质组学能对生理与病理状态下的体液、组织或细胞中基因组编码的所有蛋白质组分进行高通量的综合分析,针对筛选出的有意义“候选”蛋白（candidate protein）进行深入验证研究,不仅可能从蛋白质水平上阐明成瘾的神经生物学作用机制,还有助于建立诊断标准,发现抗成瘾药物治疗的潜在靶点。     

线粒体蛋白质组学研究进展

线粒体是真核生物中重要的细胞器,其包含的全部蛋白质称为线粒体蛋白质组。人类线粒体大约包含1500多种蛋白质,由核基因和线粒体基因共同编码。线粒体是细胞能量合成和物质代谢的中心,其功能障碍将直接或问接引起许多疾病。目前线粒体蛋白质组学正是系统性地研究线粒体在生理、病理过程中的功能变化以及研究疾病发生机制的重要方法。将线粒体蛋白质组的研究方法、研究进展、线粒体蛋白质组的性质及其在相关疾病研究中的作用进行综述,并对线粒体蛋白质组学在疾病发生机制和诊断治疗中的发展前景进行展望。     

间充质干细胞外泌体在阿尔兹海默症治疗中的研究进展

阿尔兹海默症（AD）是一种病理机制复杂,以进行性认知功能障碍为主的中枢神经系统疾病,目前仍缺乏有效的治疗方法。多项研究结果显示,间充质干细胞（MSCs）外泌体能够促进抗炎、调节免疫功能、加强Aβ降解、促进神经细胞轴突生长等,能很好地针对AD的核心病理机制发挥效果从而达到治疗效果。本文主要介绍MSCs外泌体在各项AD病理机制治疗中的研究进展。     

综述与专论：表观遗传修饰调控阿尔茨海默病的研究进展

阿尔茨海默病（Alzheimer’s disease,AD）是一种临床上常见的以进行性认知功能障碍和记忆减退为主要特征的神经退行性疾病。近些年研究发现，表观遗传修饰如DNA修饰、组蛋白修饰、RNA修饰及非编码RNA在Aβ沉积、Tau蛋白过度磷酸化、神经再生、突触可塑性和认知功能中发挥不同程度的调控作用，进而改善或加剧AD病理进程。临床数据表明表观遗传修饰的改变与AD风险呈显著相关性，运用药物、物理刺激、si RNA等干预手段在AD动物模型中改变表观遗传修饰水平可改善AD病理和认知能力。本文综述了不同的表观遗传修饰在AD中的调控作用，为进一步理解AD的表观遗传学机制及通过干预表观遗传修饰改善或治疗AD的可行性提供理论依据。     

基于质谱的药物蛋白质组学研究

药物蛋白质组学是蛋白质组学技术在药物发现和药物开发过程中的应用。基于质谱的药物蛋白质组学是蛋白质组学的一个分支,在药物研发过程中起了越来越重要的作用。本文就近年来基于质谱的药物蛋白质组学在药物作用机制、药物潜在靶点的筛选及疾病的耐药性机制等研究中取得的进展进行综述。     

Proteomic analysis of oxidatively modified proteins in Alzheimer's disease brain: insights into neurodegeneration.

Identification of oxidized proteins in Alzheimer's disease (AD) brain is hypothesized to lead to new insights into mechanisms of neurodegeneration and synapse loss in this dementing disorder that are associated with oxidative stress. Previous studies had shown increased oxidation of proteins in AD brain, but identifying those particular proteins that were specifically oxidized using standard immunochemical methods is a daunting task when one considers how many proteins there are in brain. To address this issue, proteomics has been used to identify specifically modified proteins in AD brain. This review outlines the nature of proteomics, the proteins identified in AD brain that are specifically oxidatively modified, and provides rational consequences related to neurodegeneration and synapse loss as sequelae to loss of function, due to oxidation and consistent with the known pathological and biochemical alteration in AD brain. The use of proteomics to learn about disease mechanisms is still embryonic, but the emerging techniques of proteomics represent a promising means to elucidate mechanisms of disease at the protein level. There are limitations to proteomics, and these, too, are discussed.     

Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB,glutamine synthase,and ubiquitin carboxy-terminal hydrolase L-1

Oxidative alterations of proteins by reactive oxygen species (ROS) have been implicated in the progression of aging and age-related neurodegenerative disorders such as Alzheimer's disease (AD). Protein carbonyls, a marker of protein oxidation, are increased in AD brain, indicating that oxidative modification of proteins is relevant in AD. Oxidative damage can lead to several events such as loss in specific protein function, abnormal protein clearance, depletion of the cellular redox-balance and interference with the cell cycle, and, ultimately, to neuronal death. Identification of specific targets of protein oxidation represents a crucial step in establishing a relationship between oxidative modification and neuronal death in AD, and was partially achieved previously in our laboratory through immunochemical detection of creatine kinase BB and beta-actin as specifically oxidized proteins in AD brain versus control brain. However, this process is laborious, requires the availability of specific antibodies, and, most importantly, requires a reasonable guess as to the identity of the protein in the first place. In this study, we present the first proteomics approach to identify specifically oxidized proteins in AD, by coupling 2D fingerprinting with immunological detection of carbonyls and identification of proteins by mass spectrometry. The powerful techniques, emerging from application of proteomics to neurodegenerative disease, reveal the presence of specific targets of protein oxidation in Alzheimer's disease (AD) brain: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. These results are discussed with reference to potential involvement of these oxidatively modified proteins in neurodegeneration in AD brain. Proteomics offers a rapid means of identifying oxidatively modified proteins in aging and age-related neurodegenerative disorders without the limitations of the immunochemical detection method.     

Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71

Alzheimer's disease (AD) is a neurodegenerative disorder in which oxidative stress has been implicated as an important event in the progression of the pathology. In particular, it has been shown that protein modification by reactive oxygen species (ROS) occurs to a greater extent in AD than in control brain, suggesting a possible role for oxidation-related decrease in protein function in the process of neurodegeneration. Oxidative damage to proteins, assessed by measuring the protein carbonyl content, is involved in several events such as loss in specific protein function, abnormal protein clearance, depletion of the cellular redox-balance and interference with the cell cycle, and, ultimately, neuronal death. The present investigation represents a further step in understanding the relationship between oxidative modification of protein and neuronal death in AD. Previously, we used our proteomics approach, which successfully substitutes for labor-intensive immunochemical analysis, to detect proteins and identified creatine kinase, glutamine synthase and ubiquitin carboxy-terminal hydrolase L-1 as specifically oxidized proteins in AD brain. In this report we again applied our proteomics approach to identify new targets of protein oxidation in AD inferior parietal lobe (IPL). The dihydropyrimidinase related protein 2 (DRP-2), which is involved in the axonal growth and guidance, showed significantly increased level in protein carbonyls in AD brain, suggesting a role for impaired mechanism of neural network formation in AD. Additionally, the cytosolic enzyme alpha-enolase was identified as a target of protein oxidation and is involved the glycolytic pathway in the pathological events of AD. Finally, the heat shock cognate 71 (HSC-71) revealed increased, but not significant, oxidation in AD brain. These results are discussed with reference to potential involvement of these oxidatively modified proteins in neurodegeneration in AD brain.     

Proteomic identification of nitrated proteins in Alzheimer's disease brain

Nitration of tyrosine in biological conditions represents a pathological event that is associated with several neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease (AD). Increased levels of nitrated proteins have been reported in AD brain and CSF, demonstrating the potential involvement of reactive nitrogen species (RNS) in neurodegeneration associated with this disease. Reaction of NO with O2- leads to formation of peroxynitrite ONOO-, which following protonation, generates cytotoxic species that oxidize and nitrate proteins. Several findings suggest an important role of protein nitration in modulating the activity of key enzymes in neurodegenerative disorders, although extensive studies on specific targets of protein nitration in disease are still missing. The present investigation represents a further step in understanding the relationship between oxidative modification of protein and neuronal death in AD. We previously applied a proteomics approach to determine specific targets of protein oxidation in AD brain, by successfully coupling immunochemical detection of protein carbonyls with two-dimensional polyacrylamide gel electrophoresis and mass spectrometry analysis. In the present study, we extend our investigation of protein oxidative modification in AD brain to targets of protein nitration. The identification of six targets of protein nitration in AD brain provides evidence to the importance of oxidative stress in the progression of this dementing disease and potentially establishes a link between RNS-related protein modification and neurodegeneration.     

Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1-42)

Alzheimer's disease is a progressive neurodegenerative disease associated with loss of memory and cognition. One hallmark of AD is the accumulation of amyloid beta-peptide (Abeta), which invokes a cascade of oxidative damage to neurons that can eventually result in neuronal death. Several markers of oxidative stress have been identified in AD brain, thus providing greater understanding into potential mechanisms involved in the disease pathogenesis and progression. In the present article, we review the application of redox proteomics to the identification of oxidized proteins in AD brain and also our recent findings on amyloid beta-peptide (Abeta)-associated in vivo and in vitro models of AD. Our redox proteomics approach has made possible the identification of specifically oxidized proteins in Alzheimer's disease (AD) brain, providing for the first time evidence on how oxidative stress plays a crucial role in AD-related neurodegeneration. The information obtained has great potential to aid in determining the molecular pathogenesis in and detecting disease markers of AD, as well as identifying potential targets for drug therapy in AD. Application of redox proteomics to study cellular events, especially related to disease dysfunction, may provide an efficient tool to understand the main mechanisms involved in the pathogenesis and progression of oxidative stress-related neurodegenerative disorders.     

Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration

Proteomics involves the identification of unknown proteins following their separation, often using two-dimensional electrophoresis, digestion of particular proteins of interest by trypsin, determination of the molecular weight of the resulting peptides, and database searching to make the identification of the proteins. Application of proteomics to Alzheimer's disease (AD), the major dementing disorder of the elderly, has just begun. Differences in protein expression and post-translational modification (mostly oxidative modification) of proteins from AD brain and peripheral tissue, as well as in brain from rodent models of AD, have yielded insights into potential molecular mechanisms of neurodegeneration in this dementing disorder. This review surveys the proteomics studies relevant to AD, from which new understandings of the pathology, biochemistry, and physiology of AD are beginning to emerge.     

阿尔茨海默病中的β-淀粉样蛋白和Tau蛋白

阿尔茨海默病(Alzheimer’s disease,AD)是与年龄相关的神经退行性疾病。记忆障碍通常是AD最早期和最明显的特征。β-淀粉样蛋白(amyloid-β,Aβ)沉淀(老年斑)、Tau蛋白引起的神经纤维缠结是AD的典型病理特征。许多研究证实两者之间存在着极为复杂的互为因果关系,共同造成神经元的损害。     

Proteomic Profiling and Neurodegeneration in Alzheimer's Disease

Quantitative proteome analysis of Alzheimer's disease (AD) brains was performed using 2-D gels to identify disease specific changes in protein expression. The task of characterizing the proteome and its components is now practically achievable because of the development and integration of four important tools: protein, EST, and complete genome sequence databases, mass spectrometry, matching software for protein sequences and protein separation technology. Mass spectrometry (MS) instrumentation has undergone a tremendous change over the past decade, culminating in the development of highly sensitive, robust instruments that can reliably analyze biomolecules, particularly proteins and peptides; we identified 35 proteins from over 100 protein spots on a 2-D gel. Using this current technology, protein-expression profiling, which is actually a specialized form of mining, is an important principal application of proteomics. The information obtained has tremendous potential as a means of determining the pathogenesis, and detecting disease markers and potential targets for drug therapy in AD.     

Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders

Neurodegenerative disorders (ND) belong to the most devastating diseases in the industrialized western world. Alzheimer disease (AD) is the most prevalent among these disorders followed by Parkinson disease (PD). Huntington disease (HD) is an autosomal dominantly inherited condition with a single mutation that causes disease in almost 100% of all cases. In this review we used previously published proteomics studies on AD, PD and HD to find cellular pathways changed similarly in ND and aging. All studies employed large gel two dimensional gel electrophoresis for protein separation and mass spectrometry for protein identification. Altered proteins were subjected to a KEGG pathway analysis and altered pathways determined for each disorder and aging. We found that besides the mitochondrial oxidative phosphorylation, the proteasome system are altered in aging and ND. The proteasome facilitates protein degradation which is commonly perturbed in ND which may link neurodegeneration to its largest risk factor—aging.     

An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach

Down syndrome (DS) is one of the most common causes of intellectual disability, owing to trisomy of all or part of chromosome 21. DS is also associated with the development of Alzheimer disease (AD) neuropathology after the age of 40 years. To better clarify the cellular and metabolic pathways that could contribute to the differences in DS brain, in particular those involved in the onset of neurodegeneration, we analyzed the frontal cortex of DS subjects with or without significant AD pathology in comparison with age-matched controls, using a proteomics approach. Proteomics represents an advantageous tool to investigate the molecular mechanisms underlying the disease. From these analyses, we investigated the effects that age, DS, and AD neuropathology could have on protein expression levels. Our results show overlapping and independent molecular pathways (including energy metabolism, oxidative damage, protein synthesis, and autophagy) contributing to DS, to aging, and to the presence of AD pathology in DS. Investigation of pathomechanisms involved in DS with AD may provide putative targets for therapeutic approaches to slow the development of AD.